Showing 1 - 6 results of 6 for search 'Juraj Duras', query time: 0.04s Refine Results
  1. 1
    P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma

    P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma by Heidi Mocikova, Jana Markova, Lubica Gaherova, Maria Maco, Alice Sýkorová, David Belada, Marie Lukášová, Vit Prochazka, Juraj Duras, Tomas Kozak

    Published 2022-10-01
    Get full text
    Article
  2. 2
    Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry

    Peripheral T-Cell Lymphomas Involving the Central Nervous System: A Report From the Czech Lymphoma Study Group Registry by Heidi Mocikova, Robert Pytlík, Katerina Benesova, Andrea Janikova, Juraj Duras, Alice Sykorova, Katerina Steinerova, Vit Prochazka, Vit Campr, David Belada, Marek Trneny

    Published 2022-05-01
    Get full text
    Article
  3. 3
    Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP

    Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP by Vít Procházka, David Belada, Andrea Janíková, Kateřina Benešová, Heidi Mociková, Juraj Ďuraš, Jan Pirnos, Kateřina Kopečková, Vít Campr, Tomáš Fürst, Robert Pytlík, Alice Sýkorová, Jozef Michalka, Jitka Dlouhá, Tomáš Papajík, Marek Trněný

    Published 2020-07-01
    Get full text
    Article
  4. 4
    P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.

    P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic. by Jozef Michalka, Jana Marková, Ľubica Gahérová, Mária Maco, Vít Procházka, Jan Kořen, Alice Sýkorová, Pavla Štěpánková, Kateřina Steinerová, Lekaa Mohammad, Juraj Ďuraš, Barbora Velacková, Tomáš Doležal, Kateřina Benešová, Marie Lukášová, Andrea Janíková, Zdeněk. Král., Heidi Móciková

    Published 2022-10-01
    Get full text
    Article
  5. 5
    One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

    One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID‐19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, C... by Ondrej Šušol, Barbora Šušolová, Ondřej Klempíř, Milan Navrátil, Jaromír Gumulec, Zdeněk Kořístek, Juraj Ďuraš, Michal Kaščák, Jana Mihályová, Lukáš Stejskal, Tomáš Jelínek, Petra Richterová, Lenka Szeligová, Hana Plonková, Jana Zuchnická, Barbora Dluhošová, Ivo Demel, David Buffa, Katarína Hradská, Tereza Popková, Ludmila Muroňová, Martin Lachnit, Klára Lančová, Roman Hájek

    Published 2024-12-01
    Get full text
    Article
  6. 6
    Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration

    Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell a... by Alice Sýkorová, František Folber, Kamila Polgárová, Heidi Móciková, Juraj Ďuraš, Kateřina Steinerová, Aleš Obr, Adriana Heindorfer, Miriam Ladická, Ľubica Lukáčová, Erika Čellárová, Ivana Plameňová, David Belada, Andrea Janíková, Marek Trněný, Tereza Jančárková, Vít Procházka, Andrej Vranovský, Margaréta Králiková, Jan Vydra, Lukáš Smolej, Ľuboš Drgoňa, Martin Sedmina, Eva Čermáková, Robert Pytlík

    Published 2024-09-01
    Get full text
    Article

Search Tools: